Use of Predictive Biomarkers, Incorporating Chemotherapy—What Is Best When Using Immunotherapy in Advanced NSCLC?

Cigarette Sales Up in U.S. for the First Time in 20 Years

New Warranty, Rebate Programs Put Spotlight on Value in Lung Cancer

Atezolizumab Approved for Adjuvant NSCLC Therapy for Patients with Stage II-IIIA Disease, PD-L1 ≥ 1%

First New Second-line Therapy for SCLC in Australia in 20 Years

Sotorasib Scores Second-line Approval in Canada

Savolitinib Approved in China for MET-Positive NSCLC

Durvalumab Plus Chemotherapy Approved in China as First-Line Management of Extensive-stage SCLC

First Comprehensive Genomic Profiling Assay Approved for Use with Brigatinib, ALK-positive NSCLC

Selpercatinib Approved in Canada for Metastatic NSCLC with RET Fusions

Sotorasib Wins Approval for Unmet Need in KRAS G12C-Driven NSCLC

Tepotinib Approved for MET Exon 14 Skipping Mutated Metastatic NSCLC